Toho Yakuhin To Merge With Sentai Drug Wholesaler Asucome
This article was originally published in PharmAsia News
Executive Summary
Sentai-based drug wholesaler Asucome agreed Jan. 9 to consolidate its business with Toho Yakuhin. According to the agreement, Asucome will merge with Toho by Oct.1. Asucome is an active player in the drug wholesale and dispensing drug store business; the company covers Ibaragi Prefecture and the Tohoku region except Akita Prefecture. With the merger, Toho aims to synergize operations with Asucome for procurement, distribution and marketing. (Click here for more - Japanese language
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.